2 top UK growth stocks I’m buying for my Stocks and Shares ISA in July

Looking for UK-listed growth firms to add to a Stocks and Shares ISA? Our writer highlights two he’s planning to buy this summer.

| More on:

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There are plenty of UK growth stocks currently trading at attractive valuations. Higher interest rates are keeping many investors away from this part of the market. So this is creating opportunities for patient investors looking to inject a bit of oomph into their Stocks and Shares ISAs.

Here are two growth stocks on my buy list for July.

Ashtead Technology

While many smaller stocks have been hammered in recent years, Ashtead Technology (LSE: AT.) has gone from strength to strength. In fact, it’s up 345% since listing in late 2021, and 85% over the last year.

Ashtead Technology — not to be confused with the FTSE 100‘s Ashtead Group, which it was originally part of — is a subsea equipment rental company. It hires out everything from seabed inspection cameras to winches and dredging systems.

It works with global blue-chip customers as they focus on the energy transition, both in offshore wind and the decommissioning of oil and gas infrastructure. Many of these are increasingly opting to rent equipment to lower capital expenditure.

One big reason for its share price success is that the firm’s profits have been growing nicely alongside a surging top line. Last year, revenue increased 51% year on year to £110m, with growth across all geographic markets. This was made up of 35% organic growth and the rest from acquisitions.

Gross margins improved to 78% from 74%, while adjusted earnings per share (EPS) surged 73% to 33.4p.

One thing to note here is that the firm will likely pursue more acquisitions. While these can fuel growth, they also increase debt, which increases risk.

So far though, the company has an excellent track in this department. Its return on invested capital (ROIC) is a healthy 28%.

The stock’s trading on a forward price-to-earnings (P/E) ratio of 18.8, which is attractive for a high-growth business.

Looking ahead, the company’s perfectly placed to benefit from the energy transition. It should enjoy strong structural growth in offshore wind, as well as steady growth across oil and gas (both in maintenance and decommissions).

Analysts expect the company’s revenue to nearly double to £200m by the end of 2026.

Creo Medical

The next stock, Creo Medical (LSE: CREO), has certainly taken a hammering in recent years. The share price is down 80% since mid-2019. Ouch!

Yet the medical device firm has never been in a better position than today. It specialises in electrosurgical instruments for endoscopic (minimally invasive) surgery.

Its flagship product is called Speedboat Inject. Surgeons use this device to dissect, cut out, inject, and more, when operating on patients with pre-cancerous or malignant lesions.

Creo plans to launch more products and is already licencing out its core technology to robotic companies such as Intuitive Surgical. In November, it released Speedboat UltraSlim, a more slender version with advanced features. Worldwide adoption of this device has been strong.

Last year, revenue rose 13% to £30.8m. But with a 119% increase in the user base of its technology, revenue is forecast to accelerate to £40m in 2024 (30% growth), then to £53.6m in 2025 (34%).  

One risk here is that Creo is still loss-making. It reported an operating loss of £24.5m last year. However, that was down from £30.9m in 2022, and the company’s aiming to reach cash flow break-even in 2025.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in Ashtead Group Plc, Ashtead Technology Plc, Creo Medical, and Intuitive Surgical. The Motley Fool UK has recommended Ashtead Technology Plc and Intuitive Surgical. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

I reckon these 2 penny shares are hidden gems worth a closer look!

Some penny shares are well-known, whereas many others go under the radar, but that doesn’t necessarily mean they aren’t potentially…

Read more »

Investing Articles

Just released: our 3 best dividend-focused stocks to buy before August [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Investing Articles

2 FTSE 100 shares with blockbuster yields investors should consider buying

Our writer has noticed that these FTSE 100 shares offer mammoth dividend yields, and reckons investors should take a closer…

Read more »

Stack of British pound coins falling on list of share prices
Investing Articles

Down 36% and yielding 7.8%, is this FTSE 250 share a bargain?

Christopher Ruane looks at a FTSE 250 share with a sizeable dividend yield and a recent record of dividend growth.…

Read more »

Investing Articles

Is Barclays one of the FTSE 100’s best bargain stocks?

Right now, Barclays' shares are cheaper than those of FTSE 100 rival stocks Lloyds and NatWest. So should I buy…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

Is a takeover offer about to boost the Rentokil stock price, and should I buy?

The Rentokil share price is up 10% on takeover rumours. Is it a stock to buy or one to be…

Read more »

Investing Articles

Here’s my Rolls-Royce dividend forecast for 2024-27!

Our writer considers whether the Rolls-Royce dividend might be reinstated in coming years, based on financial performance and stated payout…

Read more »

Investing Articles

What would I do if Rolls-Royce shares plunged 50%? History suggests a big decline is coming

While Rolls-Royce shares have delivered massive outperformance in recent years, they also have a history of significant declines.

Read more »